Literature DB >> 12056931

Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease.

Sophie Chantal1, Martin Labelle, Rémi W Bouchard, Claude M J Braun, Yvan Boulanger.   

Abstract

CONTEXT: The staging of Alzheimer disease (AD) dementia could be improved by a neurometabolic analysis using magnetic resonance spectroscopy.
OBJECTIVE: To examine the correlation between regional cerebral metabolic alterations measured by proton magnetic resonance spectroscopy and neuropsychological dysfunctions in patients with early AD.
DESIGN: A case-control study.
SETTING: University hospital neurology clinic and radiology department. PARTICIPANTS: A cohort of 14 patients with mild AD and 14 control subjects paired for age and sex.
INTERVENTIONS: Single-voxel proton magnetic resonance spectroscopic brain examination (60 minutes) and a comprehensive battery of psychometric tests (2 hours). MAIN OUTCOME MEASURES: Metabolite ratios relative to unsuppressed water were calculated for magnetic resonance spectroscopic metabolites (N-acetylaspartate, choline, creatine-phosphocreatine, and myo-inositol) in the medial temporal lobes (MTLs), parietotemporal cortices (PTCs), and frontal cortices of both hemispheres. Correlations were examined between metabolic changes in an area and psychometric scores of its known regional function: MTL and verbal memory, PTC and language and visuoconstructional abilities, and frontal cortices and executive functions.
RESULTS: A significant reduction of N-acetylaspartate/water (H2O) in the left MTL and of choline/H2O in both MTLs, as well as a significant increase of myo-inositol/H2O in the right PTC were observed. Metabolic alterations in the left MTL were correlated with a loss of verbal memory, in the left PTC with language impairment, and in the right PTC with a loss of visuoconstructional abilities in the group with AD.
CONCLUSION: These findings are consistent with regional distribution of neuropathologic changes and cognitive symptoms characterizing early phases of AD, and with the pattern of lateralization of normal brain function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12056931     DOI: 10.1001/archneur.59.6.955

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  23 in total

1.  Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.

Authors:  Pedro J Modrego; Miguel A Pina; Nicolás Fayed; Marcos Díaz
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 2.  Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Annu Rev Clin Psychol       Date:  2013-01-07       Impact factor: 18.561

Review 3.  Metabolic disturbances in diseases with neurological involvement.

Authors:  João M N Duarte; Patrícia F Schuck; Gary L Wenk; Gustavo C Ferreira
Journal:  Aging Dis       Date:  2013-11-30       Impact factor: 6.745

Review 4.  Various MRS application tools for Alzheimer disease and mild cognitive impairment.

Authors:  F Gao; P B Barker
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-17       Impact factor: 3.825

5.  Quantifying global-brain metabolite level changes with whole-head proton MR spectroscopy at 3T.

Authors:  Matthew S Davitz; William E Wu; Brian J Soher; James S Babb; Ivan I Kirov; Jeffrey Huang; Girish Fatterpekar; Oded Gonen
Journal:  Magn Reson Imaging       Date:  2016-08-28       Impact factor: 2.546

6.  Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study.

Authors:  Jonathan M Schott; Chris Frost; David G MacManus; Fowzia Ibrahim; Adam D Waldman; Nick C Fox
Journal:  Brain       Date:  2010-08-25       Impact factor: 13.501

7.  Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients.

Authors:  L L Chao; N Schuff; J H Kramer; A T Du; A A Capizzano; J O'Neill; O M Wolkowitz; W J Jagust; H C Chui; B L Miller; K Yaffe; M W Weiner
Journal:  Neurology       Date:  2005-01-25       Impact factor: 9.910

Review 8.  Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease.

Authors:  Evelin L Schaeffer; Orestes V Forlenza; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-10-14       Impact factor: 4.530

9.  Single voxel magnetic resonance spectroscopy at 3 Tesla in a memory disorders clinic: early right hippocampal NAA/Cr loss in mildly impaired subjects.

Authors:  Maria T Caserta; Ann Ragin; Adriana P Hermida; R John Ahrens; Leon Wise
Journal:  Psychiatry Res       Date:  2008-10-19       Impact factor: 3.222

10.  Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.

Authors:  H Randall Griffith; Jan A den Hollander; Ozioma C Okonkwo; Timothy O'Brien; Ray L Watts; Daniel C Marson
Journal:  Alzheimers Dement       Date:  2008-11       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.